Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Yeh Chen LeeMadeleine T KingRachel L O'ConnellAnne LanceleyFlorence JolyFelix HilpertAlison DavisFelicia T RoncolatoAikou OkamotoJane BrycePaul DonnellanAmit M OzaElisabeth Avall-LundqvistJonathan S BerekJonathan A LedermannDominique BertonJalid SehouliAmanda FeeneyMarie-Christine KaminskyKatrina DiamanteMartin R StocklerMichael L Friedlandernull nullPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.